Drug Profile
Treosulfan - Medac
Alternative Names: CB-2562; CB-40067; CCRIS 2781; Dihydroxybusulphan; HSDB-6963; NSC 39069; Ovastat; TrecondyvLatest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator Medac
- Developer Center for International Blood and Marrow Transplant Research; Fondazione San Raffaele; Medac; Medexus Pharmaceuticals
- Class Antineoplastics; Butylene glycols; Mesylates; Small molecules
- Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia; Myelodysplastic syndromes; Ovarian cancer
- Phase II Haematological malignancies; Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders; Myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- No development reported Renal cell carcinoma; Small cell lung cancer; Solid tumours
- Discontinued Malignant melanoma
Most Recent Events
- 12 Jan 2023 Medexus pharmaceuticals announces intention to resubmit NDA to US FDA for Acute myeloid leukaemia and Myelodysplastic syndromes (in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation) in USA
- 19 Sep 2022 Medac receives second notice of incomplete response from US FDA for treosulfan NDA resubmission
- 09 Sep 2022 Medac plans a phase I pharmacokinetics trial (Combination therapy, In adults, In elderly) (IV) in October 2022 (NCT05534620)